Choice of injectable opioid treatment may help former inmates stay on track

NCT ID NCT06880718

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot trial tests two long-acting injectable buprenorphine medications (Sublocade and Brixadi) in 60 incarcerated individuals with opioid use disorder who are about to be released from prison. Participants either choose their preferred medication or are randomly assigned one. The study tracks how well they stay in treatment, their opioid use, and their satisfaction over six months after release. The goal is to see if giving people a choice improves treatment retention and outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Buprenorphine (extended-release injectable formulations: Sublocade and Brixadi)
What this could lead to
If this trial succeeds, it could show that giving people leaving prison a choice of injectable buprenorphine helps them stay in treatment longer and reduces opioid relapse after release.
What could go wrong
This is a small pilot study with only 60 participants, so results may not apply to everyone. It compares two similar drugs, so differences may be small, and long-term effects are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BUPRENORPHINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Rhode Island Department of Corrections

    RECRUITING

    Cranston, Rhode Island, 02920, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.